Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARL | Q9H300 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15992540 | 0.90 | — | — | |
| SCHEMBL14501470 | 0.84 | — | — | |
| SCHEMBL18624614 | 0.81 | — | — | |
| SCHEMBL15991983 | 0.81 | MGLL (0.30) | — | |
| SCHEMBL15991662 | 0.80 | — | — | |
| SCHEMBL17072474 | 0.79 | — | — | |
| SCHEMBL17822946 | 0.79 | KMT2A (0.33) | — | |
| SCHEMBL21227211 | 0.79 | PARL (0.34) | PARL | |
| SCHEMBL20047186 | 0.78 | LMNA (0.33) | — | |
| SCHEMBL15503056 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109677-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SIGILON THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-12522571-B2 | Compounds, devices, and uses thereof | SIGILON THERAPEUTICS, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-20240279187-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SIGILON THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| US-11945786-B2 | Compounds, devices, and uses thereof | SIGILON THERAPEUTICS, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| US-20200039943-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SIGILON THERAPEUTICS, INC. | 2020-02-06 | — | — | US | disclosed |
| US-20200039943-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SIGILON THERAPEUTICS, INC. | 2020-02-06 | — | — | US | disclosed |
| WO-2018067615-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SIGILON THERAPEUTICS, INC. (US) | 2018-04-12 | — | — | WO | disclosed |
| US-8357377-B2 | Drug carriers; such as nucleic acids; sustained release; biocompatibility polymer | CERULEAN PHARMA INC. | 2013-01-22 | — | — | US | disclosed |
| US-8071737-B2 | Nucleic acid ligand complexes | Glead Sciences, Inc. (US) | 2011-12-06 | — | — | US | disclosed |
| US-20110212030-A1 | Nucleic Acid Ligand Complexes | GILEAD SCIENCES, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-20100273724-A1 | PEGYLATED ION CHANNEL MODULATING COMPOUNDS | CARDIOME PHARMA CORP. (CA) | 2010-10-28 | — | — | US | disclosed |
| US-7786119-B2 | Drug conjugates of ion channel modulating compounds | CARDIOME PHARMA CORP. (CA) | 2010-08-31 | — | — | US | disclosed |
| US-20080111066-A1 | Derivatization and low level detection of drugs in biological fluid and other solution matrices using a proxy marker | AFFYMAX, INC. | 2008-05-15 | — | — | US | disclosed |
| US-20080021005-A1 | Pegylated Ion Channel Modulating Compounds | CARDIOME PHARMA CORP. (CA) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021005-A1 | Pegylated Ion Channel Modulating Compounds | KCNN3, KCNN2, KCNN1 | PARL 3135/4885 |
| US-20110212030-A1 | Nucleic Acid Ligand Complexes | TLR9, SNRPE, HAVCR2 | PARL 2215/4885 |
| US-20200039943-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SLC10A1, SLCO1B3, SLC5A1 | PARL 844/4885 |
| US-20100273724-A1 | PEGYLATED ION CHANNEL MODULATING COMPOUNDS | KCNN3, KCNN2, KCNN1 | PARL 3135/4885 |
| US-11945786-B2 | Compounds, devices, and uses thereof | SLC10A1, SLCO1B3, SLC5A1 | PARL 844/4885 |
| US-20240279187-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SLC10A1, SLCO1B3, SLC5A1 | PARL 844/4885 |
| US-20260109677-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | NR3C2, AGTR1, CHRM1 | PARL 2777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.